These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34103340)

  • 1. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study.
    Verboon C; Harbo T; Cornblath DR; Hughes RAC; van Doorn PA; Lunn MP; Gorson KC; Barroso F; Kuwabara S; Galassi G; Lehmann HC; Kusunoki S; Reisin RC; Binda D; Cavaletti G; Jacobs BC; ;
    J Neurol Neurosurg Psychiatry; 2021 Oct; 92(10):1080-1088. PubMed ID: 34103340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study.
    Verboon C; van den Berg B; Cornblath DR; Venema E; Gorson KC; Lunn MP; Lingsma H; Van den Bergh P; Harbo T; Bateman K; Pereon Y; Sindrup SH; Kusunoki S; Miller J; Islam Z; Hartung HP; Chavada G; Jacobs BC; Hughes RAC; van Doorn PA;
    J Neurol Neurosurg Psychiatry; 2020 Feb; 91(2):113-121. PubMed ID: 31586949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002063. PubMed ID: 25238327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin therapy for HIV-associated Guillain-Barré syndrome.
    Wang J; Zhang Y; Wang M; Ren Y; Tang M; Liu L; Zhou D
    Int Immunopharmacol; 2022 Nov; 112():109192. PubMed ID: 36155283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
    J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.
    Fokkink WR; Walgaard C; Kuitwaard K; Tio-Gillen AP; van Doorn PA; Jacobs BC
    JAMA Neurol; 2017 Feb; 74(2):189-196. PubMed ID: 28027337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.
    van Koningsveld R; Schmitz PI; Meché FG; Visser LH; Meulstee J; van Doorn PA;
    Lancet; 2004 Jan; 363(9404):192-6. PubMed ID: 14738791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2012 Jul; (7):CD002063. PubMed ID: 22786476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
    Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
    J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of intravenous immunoglobulin retreatment amongst Guillain-Barré syndrome patients who poorly responded to initial IVIG cycle: a systematic review.
    Prado MB; Adiao KJB; Turalde CWR; Dasig DA
    Acta Neurol Belg; 2024 Aug; 124(4):1237-1250. PubMed ID: 38553651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient characteristics and the effects of intravenous immunoglobulin in patients with Guillain-Barre syndrome.
    Guzey Aras Y; Tanik O; Dogan Güngen B; Kotan D
    Ideggyogy Sz; 2016 Nov; 69(11-12):389-395. PubMed ID: 29733556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
    van Doorn PA
    Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-Term Prognosis of Mechanically Ventilated Patients With Guillain-Barré Syndrome Is Worsened by Corticosteroids as an Add-On Therapy.
    Wu X; Zhang B; Li C; Shen D; Liu K; Zhu J; Zhang HL
    Medicine (Baltimore); 2015 Oct; 94(43):e1898. PubMed ID: 26512609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin and Guillain-Barré syndrome.
    Harel M; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):281-7. PubMed ID: 16391403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of Guillain-Barré syndrome following intravenous immunoglobulin compared to natural course.
    Kalita J; Misra UK; Chaudhary SK; Das M; Mishra A; Ranjan A; Kumar M
    Eur J Neurol; 2022 Oct; 29(10):3071-3080. PubMed ID: 35837807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose immunoglobulin therapy for Guillain-Barré syndrome in Japanese children.
    Yata J; Nihei K; Ohya T; Hirano Y; Momoi M; Maekawa K; Sakakihara Y;
    Pediatr Int; 2003 Oct; 45(5):543-9. PubMed ID: 14521529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; van den Berg B; Doets AY; Leonhard SE; Verboon C; Huizinga R; Drenthen J; Arends S; Budde IK; Kleyweg RP; Kuitwaard K; van der Meulen MFG; Samijn JPA; Vermeij FH; Kuks JBM; van Dijk GW; Wirtz PW; Eftimov F; van der Kooi AJ; Garssen MPJ; Gijsbers CJ; de Rijk MC; Visser LH; Blom RJ; Linssen WHJP; van der Kooi EL; Verschuuren JJGM; van Koningsveld R; Dieks RJG; Gilhuis HJ; Jellema K; van der Ree TC; Bienfait HME; Faber CG; Lovenich H; van Engelen BGM; Groen RJ; Merkies ISJ; van Oosten BW; van der Pol WL; van der Meulen WDM; Badrising UA; Stevens M; Breukelman AJ; Zwetsloot CP; van der Graaff MM; Wohlgemuth M; Hughes RAC; Cornblath DR; van Doorn PA;
    Lancet Neurol; 2021 Apr; 20(4):275-283. PubMed ID: 33743237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.
    Korinthenberg R; Schessl J; Kirschner J; Mönting JS
    Pediatrics; 2005 Jul; 116(1):8-14. PubMed ID: 15995024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IVIG treatment and prognosis in Guillain-Barré syndrome.
    van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
    J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.